Dublin, Aug. 25, 2017 -- The "United States Insulin Pump Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022" report has been added to Research and Markets' offering.
This is the 2nd latest edition report published by the Market Report Publisher. United States Insulin Pump Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022 provides a deep and thorough evaluation of the United States Insulin Pump Market. The report provides an in-depth analysis of the type 1, type 2 and newly diagnosed type 1 diabetes and overall diabetes population.
Market growth can be attributed to factors such as increasing number of diabetic patients, growing awareness towards diabetes, improved glucose control and flexible, lifestyle-compatible treatment options and technological advancement in insulin pump devices. However, high cost of the insulin pump devices is expected to hamper growth of the market during forecast period.
It provides essential insights into insulin pump users with more focused on type 1 and type 2 diabetes insulin pump users. Market outlook in value terms has been analysed based on current and potential trends and the market is estimated from 2017 to 2022. Additionally, the report includes assessment of clinical trials and preferred insulin pump brand by the patients. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the United States Insulin Pump Market.
The report concludes with the profiles of major players in the Insulin Pump Market such as Insulet Corporation, Medtronic, Roche, Animas Corporation and Tandem Diabetes Care. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of the Insulin Pump and Diabetes Market from 2011 to 2022.
Key Topics Covered in the Report:
- United States Diabetes Population (2011 - 2022)
- United States Insulin Pump Users and Market Analysis (2011 - 2022)
- United States Insulin Pump Preferred Brand - By Product
- United States Insulin Pump Market: Reimbursement & Regulation System
- United States Insulin Pump Market - Major Deal Types
- Insulin Pump Market Clinical Trail Insight by Phase, Company & Country
- Key Companies Analysis
- Key Drivers and Inhibitors of the United States Insulin Pump Market
Key Companies Covered in the Report are as follows:
- Insulet Corporation
- Medtronic
- Roche
- Animas Corporation and
- Tandem Diabetes Care
Key Topics Covered:
1. Executive Summary
2. United States Diabetes Population (2011 - 2022): An Analysis
2.1 Overall Diabetes Population
2.1.1 Type 1 Diabetes
2.1.2 Type 2 Diabetes
2.1.3 Newly Diagnosed Type 1 Diabetes
3. United States Insulin Pump Market Analysis (2011- 2022)
3.1 Insulin Pump Users
3.1.1 Type 1 Diabetes Insulin Pump Users
3.1.2 Type 2 Diabetes Insulin Pump Users
3.2 Insulin Pump Market
4. Key Drivers and Inhibitors of the United States Insulin Pump Market
4.1 Market Drivers
4.2 Inhibitors
5. United States Insulin Pump Preferred Brand - By Product
5.1 Pediatric
5.2 Adult
6. United States Insulin Pump Market: Reimbursement & Regulation System
6.1 Reimbursement System
6.2 Regulation System
7. United States Insulin Pump Market - Major Deal Types
7.1 Insulin Pump Market - Collaboration Deals
7.2 Insulin Pump Market - Licensing Agreement
7.3 Insulin Pump Market - Exclusive Agreement
7.4 Insulin Pump Market - Partnerships Deals
8. Insulin Pump Market Clinical Trail Insight by Phase, Company & Country
8.1 Year 2016
8.2 Year 2015
8.3 Year 2014
8.4 Year 2013
8.5 Year 2012
9. Key Companies Analysis
- Animas Corporation
- Insulet Corporation
- Medtronic
- Roche
- Tandem Diabetes Care
For more information about this report visit https://www.researchandmarkets.com/research/jzlff3/united_states
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices , Infusions and Injectables


Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bill Ackman Eyes New Fund to Bet Against Market Complacency
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 



